Fate Therapeutics and BD Biosciences Launch BD SMC4 to Improve Cellular Reprogramming and iPS Cell Culture Applications
June 11, 2012 - (Fate) - “Fate Therapeutics, Inc. in collaboration with BD Biosciences, a segment of BD (Becton, Dickinson and Company), today announced the introduction of the first induced pluripotent stem cell (iPSC)-related product resulting from the collaboration between the two companies. BD™ SMC4 is a patent protected, pre-formulated cocktail of small molecules for improving cellular reprogramming efficiencies and for enabling single-cell passaging and flow cytometry sorting of iPSCs in feeder cell-free and other pluripotent cell culture systems.” Read Full Article
